Recombinant cancer vaccines and new vaccine targets. Interview by Jenaid Rees.

Abstract

Interview by Jenaid Rees, Commissioning Editor Jeffrey Schlom obtained his PhD from Rutgers University (NJ, USA). After obtaining his PhD, he worked at Columbia University (NY, USA) before moving in 1973 to the National Cancer Institute, National Institutes of Health (MD, USA). Since then he has served as the Chief of several sections, including his present position as the Chief of the Laboratory of Tumor Immunology and Biology in the Center for Cancer Research which he has held for the past 30 years. During this period, he has worked as an Adjunct Professor at George Washington University (Washington, DC, USA), served on the Editorial Board of several journals and holds membership in a number of committees. He holds over 30 patents and patent applications in the areas of vaccines, tumor antigens and monoclonal antibodies and has received honors and awards throughout his career. Jeffrey Schlom has been involved in translational research involving the immunotherapy of a range of carcinomas and predominantly works in the areas of tumor immunology, mechanisms of tumor cell-immune cell interactions and immune mechanisms. He has recently been working on the design and characterization of recombinant vaccines for cancer therapy.

• Authors: Jeffrey Schlom
• Journal: Expert review of vaccines (Expert Rev Vaccines) Vol. 12 Issue 10 Pg. 1121-4 (Oct 2013) ISSN: 1744-8395 [Electronic] England
• PMID: 24098990 (Publication Type: Biography, Historical Article, Interview)

Chemical References

• Cancer Vaccines
• Vaccines, Synthetic

Topics

• Cancer Vaccines (immunology, isolation & purification, therapeutic use)
• History, 20th Century
• History, 21st Century
• Humans
• Immunotherapy (methods)
• Neoplasms (immunology, therapy)
• Vaccines, Synthetic (immunology, isolation & purification, therapeutic use)